Myelodysplastic Syndrome (MDS) - Trials, Transplant and Overlap Disorders
Tracks
-
| Tuesday, April 21, 2026 |
| 2:20 PM - 3:50 PM |
| Room 11B & C, Upper Level |
Details
We are planning to focus our entire session on case-based discussion and interactive questions. The cases and discussions will focus on ongoing clinical trials in UK, with emphasis on novel therapeutic approach including transplant strategies and management of overlap disorders (CMML and MDS/MPN) available to haematologists in UK. The patient cases will focus on trial options available for low risk MDS after EPO failure and higher risk MDS beyond 5-azacytidine.
We will also focus on lower risk MDS with high risk genetic/clinical features and the blurring of boundaries between MDS & AML, from stem cell transplantation perspective. Management of MDS/MPN, especially CMML, in UK will be highlighted from the successful delivery of AMML clinical trial, with implications on UK clinical practice.
Speaker
Dr Jennifer Vidler
Haematology Specialist Registrar
King's College Hospital NHS Foundation Trust
Trials in MDS
2:20 PM - 2:45 PM
Dr. Austin Kulasekararaj
Consultant Haematologist
King's College Hospital
Trials in MDS
2:20 PM - 2:45 PM
Dr. Daniel Wiseman
Consultant Haematologist
The Christie NHS Foundation Trust
CMML and overlap disorders
2:45 PM - 3:10 PM
Dr. Selim Kimyongur
Haematology Fellow
The Christie Hospital
CMML and overlap disorders
2:45 PM - 3:10 PM
Dr Wendy Ingram
Consultant Haematologist
University Hospital of Wales
Transplant in MDS
3:10 PM - 3:35 PM
Dr. Razan Elbashir
ST7
Cardiff and Vale University Health Board
Transplant in MDS
3:10 PM - 3:35 PM
All Speakers
Panel Discussion
3:35 PM - 3:50 PM
Dr. Catherine Cargo
Consultant Haematologist
Leeds Teaching Hospitals NHS Trust
Session Chair
Dr. Pramila Krishnamurthy
Consultant Haematologist
King's College Hospital, London
Session Co-Chair
